



HAL
open science

Colonization Factor Antigens, Enterotoxigenic Escherichia coli, Enzyme-linked Immunosorbent Assay, Ganglioside GM1 , Hemagglutination

Casmir Ifeanyichukwu Cajetan Ifeanyi, Nkiruka Florence Ikeneche, Bassey Enya Bassey, Nazek Al-Gallas, Akpa Alexander Casmir, Isu Rosemary Nnennaya

► To cite this version:

Casmir Ifeanyichukwu Cajetan Ifeanyi, Nkiruka Florence Ikeneche, Bassey Enya Bassey, Nazek Al-Gallas, Akpa Alexander Casmir, et al.. Colonization Factor Antigens, Enterotoxigenic Escherichia coli, Enzyme-linked Immunosorbent Assay, Ganglioside GM1 , Hemagglutination. Jundishapur Journal of Microbiology, 2018, 11 (1), 10.5812/jjm.64269 . pasteur-02022681

HAL Id: pasteur-02022681

<https://riip.hal.science/pasteur-02022681>

Submitted on 18 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Characterization of Toxins and Colonization Factors of Enterotoxigenic *Escherichia coli* Isolates from Children with Acute Diarrhea in Abuja, Nigeria

Casmir Ifeanyichukwu Cajetan Ifeanyi,^{1*} Nkiruka Florence Ikeneche,² Bassey Enya Bassey,³ Nazek Al-Gallas,⁴ Akpa Alexander Casmir,⁵ and Isu Rosemary Nnennaya⁶

¹Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Abuja, P.M.B 117, Abuja, Nigeria

²Department of Medical Microbiology, College of Health Science, University of Abuja, P.M.B 117, Abuja, Nigeria

³World Health Organization Office, Plot 1620, Yusuf Maitama Sule Street, Off Yakubu Gowon Crescent Asokoro, Abuja

⁴Laboratoire de Controle, des Eaux et Denrees Alimentaires, Institut Pasteur de Tunis, 13 Place Pasteur, BP 74, Tunis 1002, Belvedere, Tunisie

⁵Department of Medical Biotechnology, National Biotechnology Development Agency, Abuja

⁶Department of Biological Science, Faculty of Science, University of Abuja, P.M.B 117, Abuja, Nigeria

*Corresponding author: Casmir Ifeanyichukwu Cajetan Ifeanyi, Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Abuja, P.M.B 117, Abuja, Nigeria. Tel: +2348030750990, E-mail: ifeanyi.casmir@gmail.com

Received 2016 February 15; Revised 2017 January 11; Accepted 2017 August 12.

Abstract

Background: Heat-labile (LT) and heat-stable (ST) toxin variants of enterotoxigenic *Escherichia coli* (ETEC) are enterotoxins associated with diarrhea among children in Abuja, Nigeria. Enterotoxigenic *Escherichia coli* is also known as a major etiological agent of diarrheal disease among travelers in developing countries. Continuous identification of commonly expressed bacterial components of ETEC can help extend the protective spectra of future candidate ETEC vaccines in Nigeria.

Objectives: This study aimed to provide new insights into the distribution patterns of enterotoxins, colonization factor antigens (CFA phenotypes), and serotypes and to determine the antimicrobial susceptibility patterns of ETEC strains from children with acute diarrhea in Abuja, Nigeria.

Methods: *Escherichia coli* strains, isolated from the stool samples of children aged 0 - 60 months, were tested via polymerase chain reaction, ganglioside GM₁ ELISA assay, hemagglutination assay, HEp-2 cell adherence assay, dot blot technique, and disc diffusion method for antimicrobial resistance.

Results: Enterotoxigenic *Escherichia coli* was detected in 16 (4.0%) out of 400 children with acute diarrhea. The toxigenic genotypes expressed by ETEC strains included LT toxin gene 6 (37.5%), ST toxin gene 6 (37.5%), and ST/LT gene 4 (25.0%). The CF phenotypes with major expression included CS2 (25.0%), CS3 (12.5%), and CFA1 (6.3%), with a probability value below 0.05 ($P < 0.05$). However, no CFA/CS was detected in 56.3% of ETEC strains. Multidrug resistance pattern of nalidixic acid-ciprofloxacin-amoxicillin-augmentin-cephalexin-cefuroxime was observed in 19% of ETEC strains. The most prevalent ETEC serotype was O8: H9 (n, 5). Based on the findings, ETEC infection peaked to 7.2% in July.

Conclusion: Although ST and LT toxins seem to have equal distributions in the analyzed population, continuous identification of CFA phenotypes and toxins is necessary for the evaluation of ETEC vaccines in Nigeria.

Keywords: Colonization Factor Antigens, Enterotoxigenic *Escherichia coli*, Enzyme-linked Immunosorbent Assay, Ganglioside GM₁, Hemagglutination

1. Background

Enterotoxigenic *Escherichia coli* (ETEC) has been reported as the most common cause of diarrhea in children below 5 years in developing countries (1). Enterotoxigenic *Escherichia coli* accounts for approximately 20% of all cases of diarrhea and death each year (2). As the most important cause of diarrhea in children, ETEC can be transmitted from one person to another via consumption of contaminated food or water (3).

An ETEC strain can colonize and adhere to human intestinal epithelial cells via a heterogeneous group of proteinaceous surface structures, known as colonization factors (CFs). Colonization factors can be fimbrial, nonfimbrial, or fibrillar (4). These CF structures are also referred to as CF antigen 1 (CFA/1); however, the new nomenclature suggests coli surface (CS) antigen.

So far, more than 25 CS antigens have been identified and categorized into 3 distinct families: CFA/I-like group

(CFA/I, CS1, CS2, CS4, CS14, and CS17), CS5-like group (CS5, CS7, CS18, and CS20), and a distinctive group consisting of CS3, CS6, CS10, CS11, and CS12 (2, 5, 6). Following initial adhesion and colonization, ETEC strains induce diarrhea by producing heat-labile (LT) and/or heat-stable (ST) enterotoxins, which are plasmid-encoded (7). The diagnosis of ETEC infection relies on the detection of either genes or gene products in the clinical specimens (8).

Currently, LT derivatives and CFs are targets in the development of vaccines against ETEC (8). Development of these vaccines relies on the characterization of ETEC isolates in a variety of settings. Vaccine development for ETEC is dependent on an in-depth understanding of toxins and CF distribution (9). However, considering the great variability in the distribution of ETEC toxins and CFs, variations in phenotypic, genotypic, and pathogenic properties should be investigated (10). In this regard, a study carried out in South Western Nigeria reported a significant association between ST enterotoxin-producing ETEC and diarrhea (11).

2. Objectives

In view of the undocumented disease burden of ETEC-associated diarrhea in the Federal Capital Territory (FCT, Abuja, Nigeria), this study aimed to not only determine the epidemiological characteristics of ETEC strains in children with acute diarrhea, but also investigate the presence of LT and ST toxins, distribution of CFs, and antimicrobial susceptibility pattern of the strains.

3. Methods

Escherichia coli strains analyzed in this study were obtained between January and December 2012. This study included pediatric patients with diarrhea, aged 0 - 60 months, who were selected from 2 tertiary hospitals (University of Abuja Teaching Hospital, ethic code: FCT/UATH/GEN/1085/58; National Hospital of Abuja, ethic code: NHA/ADMIN/236/V.VII/805), 2 secondary hospitals (Maitama and Nyanya districts hospitals), and 1 primary health centre (Mpape Health Centre). The included facilities were all located in Abuja, Nigeria.

In total, 400 children with acute diarrhea participated in this study. The age and sex distribution of children with acute ETEC-associated diarrhea is presented in Table 1. Stool samples were collected from children \leq 5 years, who met the inclusion criteria for diarrhea, ie, three or more loose (or watery) stools or at least 1 bloody loose stool in 24 hours. The stool specimens from diarrheic children were collected in dry, sterile, wide-mouthed, leak-proof containers. The samples were stored at 4°C in the hospitals and

transferred to the microbiology laboratory in cold boxes for analysis.

The samples were evaluated for common enteric pathogens (*Salmonella*, *Shigella*, *Vibrio*, and *Campylobacter* species, rotaviruses, and ova/cyst of parasites) via conventional methods (12). All *E. coli* isolates were individually characterized by polymerase chain reaction (PCR), using 8 virulence gene-targeted assays to assess the presence of distinct diarrheagenic *E. coli* (DEC) pathotypes, as described in the literature (13). PCR-positive ETEC colonies were analyzed using ganglioside GM₁ ELISA and GM₁ inhibition ELISA to detect the expression of LT and ST enterotoxins, respectively, as described in the literature (14-17).

Table 1. Age and Sex Distribution of Children With Acute Diarrhea Associated With Enterotoxigenic *Escherichia coli* (ETEC) in Abuja, Nigeria^a

Factors	Number of Diarrheic Subjects	Number (%) of ETEC-Positive Patients	P-Value
Age, months			0.03
0 - 5	49	1 (2.0)	
6 - 12	165	8 (4.8)	
13 - 24	116	1 (0.9)	
25 - 36	29	3 (10.3)	
37 - 48	17	0 (0.0)	
49 - 60	24	3 (12.5)	
Sex			0.03
Male	180	10 (5.6)	
Female	220	6 (2.7)	

^aOnly 1 out of 49 subjects, aged 0 - 5 months, had ETEC infection. ETEC infection in males was significantly higher than females ($P < 0.05$)

3.1. DNA Extraction

A total of 109 *E. coli* isolates (1 isolate from each strain from every child) were grown on Luria-Bertani broth (LB broth; Sigma, St. Louis, MO, USA) overnight at 37°C. Genomic DNA was extracted according to the method described by Al-Gallas et al. in 2007 (18). Briefly, DNA was released from whole organisms by boiling. Bacteria were harvested from 1.5 mL of an overnight LB culture (Sigma, St. Louis, MO), suspended in 200 μ L of sterile water, and incubated at 100°C for 15 minutes. Following lysate centrifugation, a 150- μ L sample of the supernatant was stored at -20°C in the aliquot as a template DNA stock and used as the target for PCR assays.

3.2. PCR Analysis

The PCR primers for the identification of *elt* genes (heat-labile toxin genes) included ET-LT1 (GCGACAAATTAT-

ACCGTGCT) and ET-LT2 (CCGAATTCTGTTATATATGT) (Amer-sham, Piscataway, USA). The same primers were used for *sta* genes (heat-stable toxin genes) (18, 19). Details of primer sequences, PCR conditions, and predicted size of the amplified products for the evaluation of other virulence genes, which can distinguish DEC groups, have been described previously (Table 2) (20-23). PCR was performed in an automated thermocycler (Perkin-Elmer).

The reference strains for PCR in this study were as follows: ETEC H10407 for *elt* and *sta* genes, EHEC EDL933 (O157:H7) for *stx* and *ehxA* genes (Shiga toxin gene and enterohemolysin gene, respectively), EPEC 2348/69 (O127:H6) for *eae* and *bfpA* genes (attaching and effacing *E. coli* gene and bundle-forming pilus gene, respectively), EIEC 11741 for *ipaH* gene (invasion plasmid antigen), and EAEC 17-2 for *astA* and *aaf-I* genes (heat-stable enterotoxin I and aggregative adherence fimbriae, respectively). The nonpathogenic *E. coli* strain, HB101, was used as the negative control.

3.3. GM1 ELISA and CF Immunodot Blot Assay

Strains identified as ETEC by PCR were confirmed by ganglioside GM₁ ELISA. GM₁ inhibition ELISA was performed to detect the expression of LT and ST enterotoxins, respectively as described in the literature (14, 15). Subsequently, two colonies from each strain, which were confirmed as ETEC via ELISA, were subcultured on CF agar with and without bile salts (Difco, Detroit, MI) and incubated at 37°C overnight, as described in the literature (17, 24). The expression of phenotypic CFs was tested by colony immunodot blot assay, using monoclonal antibodies against CFA/I, CS1-CS7, CFA/III (CS8), CS12 (PCFO159), CS14 (PCFO166), and CS17 (25-27).

3.4. Determination of Hemagglutination (HA) Activity

The presence of HA was tested for all GM₁ ELISA-confirmed ETEC strains, using the methods described by Evans et al. (28). Briefly, a colony from each isolate of CFA culture was suspended in 10 µL of saline on a glass slide in a repetitive order. Each slide was added 10 µL of 3% (v/v) human, bovine, chicken, and guinea pig erythrocyte suspension in saline, with or without 1% D-mannose. The slide was rotated back and forth for mixing for 5 minutes. The presence or absence of HA was scored as (-) or (+). HA was considered mannose-sensitive (MSHA) if only detected in the erythrocyte suspension without 1% D-mannose. On the other hand, HA was considered mannose-resistant (MRHA) if detected in the presence or absence of 1% D-mannose.

3.5. Serotyping of *E. coli*

The serological characterization of 16 ETEC strains into different somatic (O), flagella (H), and K1 antigens was performed at the Identification and Serotyping Laboratory of

the Enteric Diseases Program, National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health Public Health Agency of Canada (1015 Arlington St., Winnipeg, Manitoba R3E 3R2, Canada). The procedures were performed as described by Orskov and Orskov (1984) (29-31).

3.6. Antimicrobial Susceptibility

The characterized ETEC strains (n, 16) were tested for susceptibility to the following antibiotics: nalidixic acid (30 µg), ciprofloxacin (5 µg), cephalexin (30 µg), cefuroxime (30 µg), amoxicillin (25 µg), ceftriaxone (30 µg), and amoxicillin-clavulanic acid (30 µg) (Oxoid, Basingstoke, UK), using the standard Kirby-Bauer disc diffusion susceptibility method. In addition, *Escherichia coli* ATCC 25922 was used as the control.

Multidrug resistance (MDR) was defined as resistance to ≥ 2 classes of antimicrobial agents (32). The minimum inhibitory concentrations (MICs) of the isolates were determined by the broth microdilution method (Sensititre Automated Microbiology System; Trek Diagnostic Systems Ltd., Westlake, OH, USA). Using the Clinical & Laboratory Standards Institute (CLSI) guidelines, each organism was classified as either resistant or susceptible (33).

3.7. Ethics statement

Informed consent and ethical approval were obtained from the subjects and institutional ethics committees of the University of Abuja Teaching Hospital (Gwagwalada, Abuja) and National Hospital of Abuja, respectively.

3.8. Statistical Analysis

Statistical analysis was performed using SPSS version 16 with Fisher's exact test. P-value below 0.05 was considered statistically significant.

4. Results

In this study, we evaluated the prevalence of ETEC, its toxins, CFAs, and O:H serotypes associated with childhood diarrhea in FCT-Abuja, Nigeria. Enterotoxigenic *Escherichia coli* associated diarrhea was observed in all age groups, except children aged 37 - 48 months, from whom no ETEC strain was isolated. The association between ETEC and age group of 49 - 60 months was significant ($P < 0.05$). The prevalence of ETEC infection was higher in male subjects (5.6%; 10/180), compared to females (2.7%; 6/220) ($P < 0.05$; Table 1).

Table 2. PCR Primers Used to Identify the Virulence Markers of ETEC and Other Diarrheagenic *Escherichia coli* (DEC) Isolates

Gene	Primer	Oligonucleotide Sequence (5'-3')	PCR product, bp ^a	PCR Condition	Reference
Elt			708	94°C, 1 min; 56°C, 2 min; 72°C, 1 min	(19)
	ET-LT1	GCGACAAATTATACCGTGCT			
	ET-LT2	CCGAATTCTGTTATATATGT			
Sta			180	94°C, 30 sec; 55°C, 90 sec; 72°C, 90 sec	(20)
	ST5'	ATTTTCTTCTGTATGTCTT			
	ST3'	CACCCGGTACAAGCAGGATT			
Eae			790	94°C, 1 min; 55°C, 1 min; 72°C, 1 min	(21)
	fM1	CATTATGGAACGGCAGAGGT			
	rYu4	ATCTTCTGCGTACTGCGTTCA			
hfpA			324	94°C, 30 sec; 43°C, 30 sec; 72°C, 1 min	(19)
	EP1	CAATGGTGCTTGCGCTTGCT			
	EP2	GCCGCTTATCAACCTGGT			
Stx			900	94°C, 1 min; 43°C, 90 sec; 72°C, 90 sec	(22)
	LIN5'	GAACGAAATAATTATATGT			
	LIN3'	TTTGATTGTTACAGTCAT			
ehxA			321	94°C, 90 sec; 55°C, 90 sec; 72°C, 2 min	(20)
	RH35	CACACGGAGCTTATAATATTCTGTCA			
	RH37	AATGTTATCCCAATTGACATCATTGACT			
IpaH			424	94°C, 1 min; 56°C, 2 min; 72°C 1 min	(19)
	EI-1	GCTGAAAAACTCAGTGCCT			
	EI-2	CAGTCCGTAATTCATTCT			
astA			111	95°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec	(23)
	Eg1	CCATCAACACAGTATATCCGA			
	Eg2	GGTCGCGAGTGACGGCTTTGT			
aafI			432	95°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec	(23)
	AAF/I-1	GCGTTAGAAAGACCTCCAATA			
	AAF/I-2	GCCGGATCCTTAAAATTAATCCGGC			

^aThe PCR cycles consisted of denaturation, annealing, and extension

4.1. Detection of Toxins and CFs

The phenotypic characteristics of ETEC strains are illustrated in Table 3. The expression of CFA/CS antigen in ETEC strains varied significantly. In total, 16 ETEC strains expressed CFA; four (25.0%) strains expressed CS2, 2 (12.5%) strains expressed CS3, and 1 (6.3%) strain expressed CFA1. CFA/CS was not expressed in 9 (56.3% ETEC strains (5 LT and 4 ST strains). The association between CFA/CS and ETEC strains, positive for both LT and ST, was significant ($P < 0.05$). The frequencies of ETEC-ST, ETEC-LT, and ST-LT strains were 6/16 (37.5%), 6/16 (37.5%), and 4/16 (25%), respectively. Overall, 43.7% of ETEC isolates expressed CFs, while ETEC strains with no detectable CFA/CS consisted of LT (31.3%

and ST (25.0%) strains.


4.2. Demographic and Seasonal Distribution of ETEC

Demographic distribution and seasonal variation of ETEC isolates from children with acute diarrhea in Abuja, Nigeria are presented in Figure 1. Enterotoxigenic *Escherichia coli* associated diarrhea was reported throughout the study (January-December). The seasonal patterns in this study indicated that ETEC-associated diarrheal infections peaked in July (7.2%), although the difference was not significant ($P > 0.05$). The second highest prevalence of infection was recorded in December (6.6%), while lower prevalence rates were observed in August and October.

Table 3. The Phenotypic Characteristics of ETEC Isolates From Children With Acute Diarrhea in Abuja, Nigeria

Isolate ID No.	Enterotoxin Type	CFA/CS	HEp-2 cell Adherence Pattern	Serotype
006	st	-	NA	<i>Escherichia coli</i> O117:HNM
013	st	CS2	DA	<i>E. coli</i> O86:H18
014	lt	CS3	DA	<i>E. coli</i> O8:H9
015	st	-	NA	<i>E. coli</i> ORough:HNM
034	lt	-	NA	<i>E. coli</i> OUT:HNM
140	st	CFA/I	DA	<i>E. coli</i> O15:H11
189	st/lt	CS2/CS3	DA	<i>E. coli</i> O8:H9
190	st/lt	CS3/CS2	DA	<i>E. coli</i> O8:H9
234	st	-	NA	<i>E. coli</i> O86:H30
283	st	-	NA	<i>E. coli</i> ORough:HNM
290	lt	-	NA	<i>E. coli</i> O9:HUT
297	lt	-	NA	<i>E. coli</i> O9:HUT
344	st/lt	CS2/CS3	DA	<i>E. coli</i> O8:H9
345	st/lt	CS2/CS3	DA	<i>E. coli</i> O8:H9
354	lt	-	NA	<i>E. coli</i> OUT:HNM
361	lt	-	NA	<i>E. coli</i> OUT:HNM

Abbreviations: DA, diffuse adherence; NA, nonadherence; CFA/I, colonization factor antigen I; CS2, coli surface 2; CS3, coli surface 3; HNM, flagellar and nonmotile; HUT, flagellar and untypeable; OUT, O-untypable

**Figure 1.** Demographic Distribution and Seasonal Variations of Enterotoxigenic *E. coli* (ETEC) Isolates From Children With Acute Diarrhea in Abuja, Nigeria

4.3. Determination of Antimicrobial Resistance Patterns of ETEC Strains

The antimicrobial resistance patterns of ETEC strains, obtained by disc diffusion susceptibility method, are illus-

trated in Table 4. All 16 ETEC strains were resistant to at least 1 antimicrobial agent, whereas none exhibited resistance to the tested antimicrobials according to the current CLSI breakpoints. There were 7 different antimicrobial re-

sistance patterns among the ETEC strains. Overall, MDR was observed in 5/16 (31.3%) ETEC strains.

5. Discussion

Enterotoxigenic *Escherichia coli* has been identified as a major etiological agent of diarrheal disease among travelers and children below 5 years in developing countries. The prevalence of ETEC was reported to be 10.3% and 12.5% in children aged 25 - 36 and 49 - 60 months, respectively. These rates are higher than previous reports from South Western Nigeria (2.4%) (11). Similarly, recent studies from other developing countries reported an ETEC prevalence of 5.2% in children below 2 years in Peru (8) and 9.2% in Brazil (34).

In the present study, the prevalence of ETEC in children aged 49 - 60 months (12.5%) is not in agreement with the general belief that the prevalence of ETEC infection in developing countries decreases after 5 years of age (2). However, this finding is consistent with a recent report, indicating a significantly higher ETEC isolation rate among older infants (8). The discrepancy between our findings and other reports may be attributable to variations in geographical factors and target populations.

The *sta* and *elt* genes were equally distributed among ETEC isolates (37.5%); this finding is not in agreement with previous studies, which reported ST dominance in Nigeria (11) and Jakarta, Indonesia (35). However, the high prevalence of LT- and ST-producing ETEC isolates in this study was similar to the distribution of enterotoxins in other studies on diarrhea among children, including those performed in Egypt, Tunis, and Bolivia (10, 18, 36).

Studies from different parts of the world have reported the phenotypic diversity of ETEC with regard to its potential for the combination of serotypes, toxins, and CFs (1, 8, 18). The prevalence of CF ETEC strains in this study (43.7%) is lower than recent reports of ETEC strains isolated from diarrheal specimens in Egypt (64%), Peru (65%), and Bolivia (55%) (1, 8, 31). The differences in CF detection in these studies may be due to variations in the methodologies of dot blot assay and multiplex PCR for detection.

Detection of no CFA/CS in 56.3% of ETEC strains in this study is consistent with previous research, which indicated the inability to detect known CFs in approximately 30 - 50% of ETEC strains (37). This finding has been attributed to the absence of CFs, their loss, or lack of specific tools for detection (37). Moreover, lack of a defined CF has been reported to be mainly related to LT strains (10, 33), which is in agreement with the present results.

Colonization factors are usually more prevalent in ST-positive strains (26). However, we detected CFs more in ST-

and LT-positive ETEC strains, which is consistent with reports from peri-urban regions of Egypt (3). Since human infection by CF-negative ETEC strains continues to be reported, further studies are needed to determine the virulence and involvement of CF-negative ETEC strains in diarrheal disease.

In this study, a specific toxin-serotype association was observed, particularly with serotype O8: H9 among the ETEC strains. This serotype has been reported to be associated with LT-positive strains (36, 38). However, in the present study, this serotype was observed in 5 strains, all isolated from different patients; four were associated with ST/LT-positive strains, and only 1 was LT-toxin positive.

The HA assay of *E. coli* isolates revealed different patterns with various erythrocytes. Based on the HA study, 7 (43.8%) ETEC strains were MRHA, while only 1 (6.3%) was MSHA. Previous studies in Argentina and Kuala-Lumpur reported the absence of HA in 46.2% and 62.0% of ETEC strains, respectively (39, 40). In the present study, 9 (56.3%) ETEC strains failed to demonstrate any type of HA, which is in agreement with previous reports. The absence of HA in a significant proportion of ETEC isolates can be attributed to the loss of CFA encoding genes or the presence of other adhesions not associated with HA (32); the foregoing may be the case with ETEC strains in this study.

CFA I and CFA II (CS2 and CS3), which constitute only 18% of oral inactivated vaccine candidates and have been evaluated by experts, are the actual CFAs in FCT-Abuja, Nigeria. In Bangladesh, the prevalence of toxins and CFs in bacterial components of candidate ETEC vaccines has been estimated at 75% (2). This implies that the formalin-inactivated ETEC vaccine may be of limited use, as CFA I and CFA II (CS2 and CS3) are found in the bacterial components of current candidate ETEC vaccines in FCT-Abuja, Nigeria. Therefore, this vaccine may not confer protection against a number of ETEC strains prevalent in this region.

Since ETEC toxin and CF variability is indispensable (especially as formulation of ETEC vaccines is mainly based on LT toxins and common CFs) (41), it is pertinent to use a combination of maximally antigenic vaccine preparations and regimens for delivery. This can produce an optimal immune response to ETEC strains, infecting infants and children in developing countries (6). It also ensures that ETEC strains are not refractory to these vaccine preparations and underscores the relevance of our study as the first analysis and description of CFs among ETEC strains in Nigeria.

Seasonal variations in this study indicated that ETEC disease peaked during rainy seasons, although the prevalence was not significantly higher than dry seasons. Although this finding is consistent with the usual peak of infections during transition to warm and rainy seasons in tropical regions, it disagrees with the unusual seasonality

Table 4. Antimicrobial Resistance Patterns of Enterotoxigenic *Escherichia coli* (ETEC) Isolates From Children With Acute Diarrhea in Abuja, Nigeria

ETEC Toxin Type	Total Number of Strains	Antibiotic Resistance Profile	Frequency	
			No.	Percentage
<i>St</i>	6	AMX	1	16.7
		AMX, AUG	1	16.7
		AUG, CEPH	1	16.7
		NAL, AMX, AUG, CEPH, CEFU	1	16.7
		NAL, CIP, AMX, AUG, CEPH, CEFU	2	33.3
<i>Lt</i>	6	AMX, AUG	1	16.7
		AMX, AUG, CEPH	3	50.0
		AMX, AUG, CEPH, CEFU	2	33.3
<i>st/lr</i>	4	AMX, AUG, CEPH	3	75.0
		NAL, CIP, AMX, AUG, CEPH, CEFU	1	25.0

The antibiotic resistance profiles showed that 2 (33.3%) out of 3 ETEC strains with resistance patterns of NAL, nalidixic acid; CIP, ciprofloxacin; AMX, amoxicillin; AUG, augmentin; CEPH, cephalixin; CEFU, cefuroxime to 6 out of 7 tested antibiotics possessed ST toxin type, whereas the remainder possessed ST/LT toxin

for ETEC strains recently reported in Bolivia (1).

Antimicrobial resistance by ETEC strains indicated that the amoxicillin-augmentin-cephalexin resistance profile was the most common resistance pattern, while ETEC strains were susceptible to ceftriaxone. We also detected resistance to nalidixic acid and ciprofloxacin. Overall, *E. coli* resistance to quinolone has been mainly associated with mutations in *gyrA* and *parC* genes. Strains resistant to nalidixic acid are likely to have at least 1 mutation of *gyrA* gene. Although MDR was 31.3% among ETEC strains, no extended-spectrum beta-lactamase (ESBL) producers were detected among these strains. This finding is similar to a study by Al-Gallas et al. in 2007 (18). However, it should be noted that in children with acute gastroenteritis, use of specific antimicrobial drugs should be limited to well-defined bacterial agents (8).

6. Conclusion

The present analysis of ETEC-associated diarrhea among children in FCT-Abuja, Nigeria confirms that ETEC is still a major cause of diarrhea in developing countries. The findings accentuate the need for sustained nationwide epidemiological ETEC studies, as there may be a loss of CF plasmids during storage, subculturing, and processing. It should be noted that some adhesions with the potential to extend the protective spectra of future candidate vaccines might have been missed from the assays in Nigeria. This study highlights the need for major efforts towards the design of more effective vaccines for the prevention of ETEC infections, especially in endemic areas. Overall, the

present findings may be useful in this area. This study also established the role of ETEC in childhood diarrheal infections in FCT-Abuja, Nigeria. The findings underscore the need for continuous identification of more commonly expressed ETEC bacterial components as a framework for evaluating potential ETEC vaccines in Nigeria.

Acknowledgments

The authors would like to thank all those who collaborated with us in this study. We also extend our gratitude to the staff of Enteric Diseases Program (WHO Collaborating Centre) at the National Microbiology Laboratory (Canada), especially Dr. Celine Nadon, Rafiq Ahmed, Helen Tabor, and Dr. Matthew Gilmour for their assistance with serotyping. Moreover, we would like to thank the children and their parents for providing the stool samples, as well as the laboratory staff of all hospitals and health centers for their contribution to the collection of samples. Finally, we acknowledge the staff of the Department of Biological Sciences, University of Abuja for the logistic support and the Laboratoire de Controle des Eaux et Denrees Alimentaires de l'Institut Pasteur de Tunis, Tunisia for their valuable input.

Footnotes

Authors' Contributions: Casmir Ifeanyichukwu Cajetan Ifeanyi was the main researcher, who contributed to data entry, data analysis, laboratory analyses, and drafting of the manuscript. Nkiruka Florence Ikeneche participated in

the design and execution of the study. Bassey Enya Bassey reviewed the draft of the manuscript and provided advice. Nazek Al-Gallas participated in the design and execution of the study. Akpa Alexander Casmir and Isu Rosemary Nnenaya were responsible for the execution of the study and provided advice.

Financial Disclosure: The authors declare no conflicts of interest.

Funding/Support: This study was not supported by any particular grant. All the material support has been duly acknowledged.

References

- Gonzales L, Sanchez S, Zambrana S, Iniguez V, Wiklund G, Svennerholm AM, et al. Molecular characterization of enterotoxigenic *Escherichia coli* isolates recovered from children with diarrhea during a 4-year period (2007 to 2010) in Bolivia. *J Clin Microbiol*. 2013;**51**(4):1219–25. doi: [10.1128/JCM.02971-12](https://doi.org/10.1128/JCM.02971-12). [PubMed: [23390275](https://pubmed.ncbi.nlm.nih.gov/23390275/)].
- Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic *Escherichia coli* in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. *Clin Microbiol Rev*. 2005;**18**(3):465–83. doi: [10.1128/CMR.18.3.465-483.2005](https://doi.org/10.1128/CMR.18.3.465-483.2005). [PubMed: [16020685](https://pubmed.ncbi.nlm.nih.gov/16020685/)].
- Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F. Vaccines for preventing enterotoxigenic *Escherichia coli* (ETEC) diarrhoea. *Cochrane Database Syst Rev*. 2013;(7). CD009029. doi: [10.1002/14651858.CD009029.pub2](https://doi.org/10.1002/14651858.CD009029.pub2). [PubMed: [23828581](https://pubmed.ncbi.nlm.nih.gov/23828581/)].
- Croxen MA, Finlay BB. Molecular mechanisms of *Escherichia coli* pathogenicity. *Nat Rev Microbiol*. 2010;**8**(1):26–38. doi: [10.1038/nrmi-cro2265](https://doi.org/10.1038/nrmi-cro2265). [PubMed: [16020685](https://pubmed.ncbi.nlm.nih.gov/)].
- Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic *Escherichia coli* (ETEC). *Trends Microbiol*. 1996;**4**(11):444–52. [PubMed: [8950814](https://pubmed.ncbi.nlm.nih.gov/8950814/)].
- Walker RI, Steele T, Aguado T, Ad Hoc ETEC. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic *E. coli* (ETEC) disease. *Vaccine*. 2007;**25**(14):2545–66. doi: [10.1016/j.vaccine.2006.12.028](https://doi.org/10.1016/j.vaccine.2006.12.028). [PubMed: [17224212](https://pubmed.ncbi.nlm.nih.gov/17224212/)].
- Johnson TJ, Nolan LK. Pathogenomics of the virulence plasmids of *Escherichia coli*. *Microbiol Mol Biol Rev*. 2009;**73**(4):750–74. doi: [10.1128/MMBR.00015-09](https://doi.org/10.1128/MMBR.00015-09). [PubMed: [19946140](https://pubmed.ncbi.nlm.nih.gov/19946140/)].
- Rivera FP, Ochoa TJ, Maves RC, Bernal M, Medina AM, Meza R, et al. Genotypic and phenotypic characterization of enterotoxigenic *Escherichia coli* strains isolated from Peruvian children. *J Clin Microbiol*. 2010;**48**(9):3198–203. doi: [10.1128/JCM.00644-10](https://doi.org/10.1128/JCM.00644-10). [PubMed: [20631096](https://pubmed.ncbi.nlm.nih.gov/20631096/)].
- Isidean SD, Riddle MS, Savarino SJ, Porter CK. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. *Vaccine*. 2011;**29**(37):6167–78. doi: [10.1016/j.vaccine.2011.06.084](https://doi.org/10.1016/j.vaccine.2011.06.084). [PubMed: [21723899](https://pubmed.ncbi.nlm.nih.gov/21723899/)].
- Shaheen HI, Abdel Messih IA, Klena JD, Mansour A, El-Wakkeel Z, Wierzbica TF, et al. Phenotypic and genotypic analysis of enterotoxigenic *Escherichia coli* in samples obtained from Egyptian children presenting to referral hospitals. *J Clin Microbiol*. 2009;**47**(1):189–97. doi: [10.1128/JCM.01282-08](https://doi.org/10.1128/JCM.01282-08). [PubMed: [18971368](https://pubmed.ncbi.nlm.nih.gov/18971368/)].
- Okeke IN, Lamikanra A, Steinruck H, Kaper JB. Characterization of *Escherichia coli* strains from cases of childhood diarrhea in provincial southwestern Nigeria. *J Clin Microbiol*. 2000;**38**(1):7–12. [PubMed: [10618054](https://pubmed.ncbi.nlm.nih.gov/10618054/)].
- Leiva B, Lebbad M, Winiacka-Krusnell J, Altamirano I, Tellez A, Linder E. Overdiagnosis of *Entamoeba histolytica* and *Entamoeba dispar* in Nicaragua: a microscopic, triage parasite panel and PCR study. *Arch Med Res*. 2006;**37**(4):529–34. doi: [10.1016/j.arcmed.2005.10.009](https://doi.org/10.1016/j.arcmed.2005.10.009). [PubMed: [16624654](https://pubmed.ncbi.nlm.nih.gov/16624654/)].
- Ifeanyi CI, Ikeneche NF, Bassey BE, Al-Gallas N, Ben Aissa R, Boudabous A. Diarrheagenic *Escherichia coli* pathotypes isolated from children with diarrhea in the Federal Capital Territory Abuja, Nigeria. *J Infect Dev Ctries*. 2015;**9**(2):165–74. doi: [10.3855/jidc.5528](https://doi.org/10.3855/jidc.5528). [PubMed: [25699491](https://pubmed.ncbi.nlm.nih.gov/25699491/)].
- Svennerholm AM, Holmgren J. Identification of *Escherichia coli* heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. *Current Microbiol*. 1978;**1**(1):19–23.
- Svennerholm AM, Wikstrom M, Lindblad M, Holmgren J. Monoclonal antibodies against *Escherichia coli* heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. *J Clin Microbiol*. 1986;**24**(4):585–90. [PubMed: [2429984](https://pubmed.ncbi.nlm.nih.gov/2429984/)].
- Sjoling A, Wiklund G, Savarino SJ, Cohen DL, Svennerholm AM. Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic *Escherichia coli* toxins and colonization factors. *J Clin Microbiol*. 2007;**45**(10):3295–301. doi: [10.1128/JCM.00471-07](https://doi.org/10.1128/JCM.00471-07). [PubMed: [17687011](https://pubmed.ncbi.nlm.nih.gov/17687011/)].
- Evans DG, Evans DJ, Tjoo W. Hemagglutination of human group A erythrocytes by enterotoxigenic *Escherichia coli* isolated from adults with diarrhea: correlation with colonization factor. *Infect Immun*. 1977;**18**(2):330–7. [PubMed: [336541](https://pubmed.ncbi.nlm.nih.gov/336541/)].
- Al-Gallas N, Abbassi SM, Hassan AB, Aissa RB. Genotypic and phenotypic profiles of enterotoxigenic *Escherichia coli* associated with acute diarrhea in Tunis, Tunisia. *Curr Microbiol*. 2007;**55**(1):47–55. doi: [10.1007/s00284-006-0572-x](https://doi.org/10.1007/s00284-006-0572-x). [PubMed: [17554469](https://pubmed.ncbi.nlm.nih.gov/17554469/)].
- Tornieporth NG, John J, Salgado K, de Jesus P, Latham E, Melo MC, et al. Differentiation of pathogenic *Escherichia coli* strains in Brazilian children by PCR. *J Clin Microbiol*. 1995;**33**(5):1371–4. [PubMed: [7615758](https://pubmed.ncbi.nlm.nih.gov/7615758/)].
- Pradel N, Livrelli V, De Champs C, Palcoux JB, Reynaud A, Scheutz F, et al. Prevalence and characterization of Shiga toxin-producing *Escherichia coli* isolated from cattle, food, and children during a one-year prospective study in France. *J Clin Microbiol*. 2000;**38**(3):1023–31. [PubMed: [10698990](https://pubmed.ncbi.nlm.nih.gov/10698990/)].
- Beaudry M, Zhu C, Fairbrother JM, Harel J. Genotypic and phenotypic characterization of *Escherichia coli* isolates from dogs manifesting attaching and effacing lesions. *J Clin Microbiol*. 1996;**34**(1):144–8. [PubMed: [8748291](https://pubmed.ncbi.nlm.nih.gov/8748291/)].
- Bastian SN, Carle I, Grimont F. Comparison of 14 PCR systems for the detection and subtyping of stx genes in Shiga-toxin-producing *Escherichia coli*. *Res Microbiol*. 1998;**149**(7):457–72. [PubMed: [9766198](https://pubmed.ncbi.nlm.nih.gov/9766198/)].
- Monteiro-Neto V, Campos LC, Ferreira AJ, Gomes TA, Tralbulsi LR. Virulence properties of *Escherichia coli* O111:H12 strains. *FEMS Microbiol Lett*. 1997;**146**(1):123–8. [PubMed: [8997716](https://pubmed.ncbi.nlm.nih.gov/8997716/)].
- McConnell MM, Chart H, Field AM, Hibberd M, Rowe B. Characterization of a putative colonization factor (PCFO166) of enterotoxigenic *Escherichia coli* of serogroup O166. *J Gen Microbiol*. 1989;**135**(5):1135–44. doi: [10.1099/00221287-135-5-1135](https://doi.org/10.1099/00221287-135-5-1135). [PubMed: [2576034](https://pubmed.ncbi.nlm.nih.gov/2576034/)].
- Lopez-Vidal Y, Svennerholm AM. Monoclonal antibodies against the different subcomponents of colonization factor antigen II of enterotoxigenic *Escherichia coli*. *J Clin Microbiol*. 1990;**28**(9):1906–12. [PubMed: [1699969](https://pubmed.ncbi.nlm.nih.gov/1699969/)].
- Viboud GI, Binsztejn N, Svennerholm AM. Characterization of monoclonal antibodies against putative colonization factors of enterotoxigenic *Escherichia coli* and their use in an epidemiological study. *J Clin Microbiol*. 1993;**31**(3):558–64. [PubMed: [8096215](https://pubmed.ncbi.nlm.nih.gov/8096215/)].
- Qadri F, Das SK, Faruque AS, Fuchs GJ, Albert MJ, Sack RB, et al. Prevalence of toxin types and colonization factors in enterotoxigenic *Escherichia coli* isolated during a 2-year period from diarrheal patients in Bangladesh. *J Clin Microbiol*. 2000;**38**(1):27–31. [PubMed: [10618058](https://pubmed.ncbi.nlm.nih.gov/10618058/)].
- Evans DJ, Evans DG, DuPont HL. Hemagglutination patterns of enterotoxigenic and enteropathogenic *Escherichia coli* determined with human, bovine, chicken, and guinea pig erythrocytes in the presence and absence of mannose. *Infect Immun*. 1979;**23**(2):336–46. [PubMed: [370014](https://pubmed.ncbi.nlm.nih.gov/370014/)].

29. Ørskov F, Ørskov I. 2 Serotyping of Escherichia coli. *Method Microbiol.* 1984;**14**:43-112.
30. Guinee PA, Agterberg CM, Jansen WH. Escherichia coli O antigen typing by means of a mechanized microtechnique. *Appl Microbiol.* 1972;**24**(1):127-31. [PubMed: [4560465](#)].
31. Nimmich W, Straube E, Naumann G, Budde E. Detection of rough Escherichia coli K1 strains using K1 specific phages. *Fed Eur Microbiol Soc Lett.* 1981;**10**(4):353-6.
32. Vargas M, Gascon J, Casals C, Schellenberg D, Urassa H, Kahigwa E, et al. Etiology of diarrhea in children less than five years of age in Ifakara, Tanzania. *Am J Trop Med Hyg.* 2004;**70**(5):536-9. [PubMed: [15155987](#)].
33. Wayne PA. *Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th Informational Suppl.* Wayne, PA; 2006.
34. Peruski LJ, Kay BA, El-Yazeed RA, El-Etr SH, Cravioto A, Wierzbica TF, et al. Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt. *J Clin Microbiol.* 1999;**37**(9):2974-8. [PubMed: [10449484](#)].
35. Oyoyo BA, Subekti DS, Svennerholm AM, Machpud NN, Tjaniadi P, Komalarini TS, et al. Toxins and colonization factor antigens of enterotoxigenic Escherichia coli among residents of Jakarta, Indonesia. *Am J Trop Med Hyg.* 2001;**65**(2):120-4. [PubMed: [11508385](#)].
36. Rodas C, Klena JD, Nicklasson M, Iniguez V, Sjoling A. Clonal relatedness of enterotoxigenic Escherichia coli (ETEC) strains expressing LT and CS17 isolated from children with diarrhoea in La Paz, Bolivia. *PLoS One.* 2011;**6**(11). e18313. doi: [10.1371/journal.pone.0018313](#). [PubMed: [22140423](#)].
37. Steinsland H, Valentiner-Branth P, Grewal HM, Gaastra W, Molbak KK, Sommerfelt H. Development and evaluation of genotypic assays for the detection and characterization of enterotoxigenic Escherichia coli. *Diagn Microbiol Infect Dis.* 2003;**45**(2):97-105. [PubMed: [12614980](#)].
38. Merson MH, Orskov F, Orskov I, Sack RB, Huq I, Koster FT. Relationship between enterotoxin production and serotype in enterotoxigenic Escherichia coli. *Infect Immun.* 1979;**23**(2):325-9. [PubMed: [370013](#)].
39. Binsztejn N, Jouve MJ, Viboud GI, Lopez Moral L, Rivas M, Orskov I, et al. Colonization factors of enterotoxigenic Escherichia coli isolated from children with diarrhea in Argentina. *J Clin Microbiol.* 1991;**29**(9):1893-8. [PubMed: [1774313](#)].
40. Iyer L, Vadivelu J, Parasakthi N. Colonisation factors amongst clinical isolates of enterotoxigenic Escherichia coli. *Singapore Med J.* 1995;**36**(5):495-7. [PubMed: [8882532](#)].
41. McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. *Vaccine.* 2007;**25**(18):3684-91. doi: [10.1016/j.vaccine.2007.01.043](#). [PubMed: [17313998](#)].